Ivana Colaianni

Ivana Colaianni

Auto-generated profile, based on publicly available information

Ivana Colaianni

Hospital General de Agudos Donación Francisco J. Santojanni, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Prague Medical Report
Verified
Journal Article
Open access
PDF file
Guillermo Alberto KellerGuillermo Alberto Keller
Guillermo Alberto Keller
SMSilvia E Miranda
Silvia E Miranda
Adolfo de RoodtAdolfo de Roodt
Adolfo de Roodt
RSRoxana Salvi
Roxana Salvi
ICIvana Colaianni
Ivana Colaianni
JDJosé Cristian Dokmetjian
José Cristian Dokmetjian
Passive immunotherapy has been evaluated in many infections. The present study aims to evaluate purified F(ab’) 2 fraction of equine hyperimmune IgG (anti-SARS-CoV-2) in the treatment of coronavirus lung disease. Patients with coronavirus disease of 2019 (COVID-19) with World Health Organization (WHO) score 3, 4 or 5 up to 72 hours of evolution from the onset of symptoms were included. They were randomly assigned to anti-SARS-CoV-2 or placebo. Follow-up was performed for 28 days to assess efficacy, safety, pharmacokinetics, detection of anti-horse antibodies, circulating cytokines and determination of anti-SARS neutralizing activity. The 20 initial patients (44±14 years) were included. On the third day of treatment there was an improvement (P=0.02) in arterial saturation (95±1.6 vs. 93±2.5%) with increasing differences over time between treatments (day 8: 97±0.1 vs. 94±0.3%). The length of oxygen therapy treatment was 2±0.8 vs. 3±0.9 (0.048) in patients falling within WHO 5 category (no difference to WHO 4). Mean hospitalization was 13±2.5 vs. 14±0.8 days (P=0.095) and time to clinical improvement was 2±0.5 vs. 3±0.9 days (P=0.048) in patients with initial 5 WHO category, with no differences to patients who started with WHO stage 4. The time to nasal swab negativization was 10±2.1 vs. 12±0 day (P=0.015). No adverse reactions or intercurrences were detected. All patients presented heterophile antibodies without clinical correlate. The new treatment shows improvement in arterial saturation (days 3 to 12), and a decrease on detectable viral RNA (days 8 to 11) with good pharmacokinetic and safety profile.